A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

A. L. Cohn, J. Tabernero, J. Maurel, E. Nowara, J. Sastre, B. Y.S. Chuah, M. V. Kopp, D. D. Sakaeva, E. P. Mitchell, S. Dubey, S. Suzuki, Y. J. Hei, F. Galimi, I. McCaffery, Y. Pan, R. Loberg, S. Cottrell, S. P. Choo

Research output: Contribution to journalArticleResearchpeer-review

66 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences